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 1 1. Introduction 
This report provides a summary of the findings from the independent evaluation of 
the innovative Rotherham Social Prescribing Pilot being undertaken by the Centre for 
Regional Economic and Social Research (CRESR) at Sheffield Hallam University. It 
provides an assessment of the social and economic impact of the Pilot from the 
perspective of key stakeholders and follows an interim evaluation report, published in 
December 2013, which identified emerging lessons from the evaluation and provided 
a series of recommendations for stakeholders and commissioners going forward. A 
full more detailed report, including technical methodological information regarding the 
data and analysis undertaken, is also available.1  
1.1. What is social prescribing? 
Solutions for improving the health and well-being of people from marginalised and 
disadvantaged groups that place greater emphasis on preventative interventions 
have become increasingly common in public policy. Social prescribing commissions 
services that will prevent worsening health for people with existing long-term 
conditions (LTCs) and reduce costly interventions in specialist care.  It links patients 
in primary care and their carers with non-medical sources of support within the 
community.  It is tailor-made for Voluntary and Community Sector (VCS)-led 
interventions and can result in: 
 better social and clinical outcomes for people with LTCs and their carers 
 more cost-efficient and effective use of NHS and social care resources 
 a wider, more diverse and responsive local provider base. 
1.2. An overview of Social Prescribing in Rotherham 
The Rotherham Social Prescribing Pilot was delivered by Voluntary Action 
Rotherham (VAR) on behalf of NHS Rotherham CCG. It was funded for two years 
from April 2012 to March 2014 as part of a wider GP-led Integrated Case 
Management Pilot and aimed to increase the capacity of GP practices to meet the 
non-clinical needs of their patients with LTCs and their carers.  The Pilot received 
around £1m as part of a programme to provide 'additional investment in the 
community' and began receiving referrals from September 2012 onwards. 
The social prescribing model implemented in Rotherham was based around a core 
team consisting of a Project Manager and five Voluntary and Community Sector 
Advisors (VCSAs) employed by VAR, and a grant programme, which funded the 
development of new community-based services that filled gaps in provision, and 
enabled existing services to expand to meet additional demand: 
                                               
1
 http://www.shu.ac.uk/research/cresr/sites/shu.ac.uk/files/social-economic-impact-rotherham.pdf  
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 the Project Manager oversaw the day-to-day running of the Pilot, including 
management of the grant programme, and acted as a liaison between VCS 
providers and wider NHS structures. 
 VCSAs provided the link between the Pilot and multidisciplinary primary care 
teams. They received referrals from GP practices of eligible patients and carers 
and made an assessment of their support needs before referring them on to 
appropriate VCS services. 
 through the grant programme 24 VCOs received grants with a budgeted total 
value of just over £600,000.  The grants enabled these organisations to deliver a 
menu of 31 separate social prescribing services. These services acted as a 
gateway for Social Prescribing Pilot patients to access the broader range of 
services available through the wider VCS. 
 29 (out of 36) GP Practices in Rotherham referred patients to Social Prescribing. 
Overall, 1,607 patients were referred to the service of whom 1,118 were 
referred on to funded VCS services. In parallel, more than 200 referrals were 
made to non-funded VCS provision and more than 300 referrals were made to 
statutory services. 
 the five most common types of funded services referred to were: information 
and advice, community activity, physical activities, befriending and 
enabling. In addition, many of the services provided aimed to serve as a 'first 
step' for patients to access a wider range of community provision more 
independently in future. 
The Pilot covered the whole of the borough of Rotherham.  As such it was one of the 
largest of its kind, as the majority of social prescribing activity in the UK has a much 
smaller geographic focus. It has since been re-commissioned for a further year and 
forms part of Rotherham's multi-agency proposal to the Better Care Fund. 
The Pilot has also received national recognition: in March 2014 the Pilot received the 
'Excellence in Individual Participation Commissioner' award at NHS England’s 
Excellence in Participation Awards 2014. In addition, it has been influential in the 
development of NHS policy at a national level, including as part of the NHS' 
'Improving general practice - a call to action' initiative, which aims to support action 
with the potential to transform services in local communities and stimulate debate 
about how general practice can be supported to improve outcomes and tackle 
inequalities. 
Diagrammatic representation of the model is provided in Figure 1. 
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2 2. The social and economic 
impact of the Social Prescribing 
Pilot 
2.1. Impact on the demand for hospital care 
Using patient-level Hospital Episode Statistics (HES) provided by the Commissioning 
Support Unit (CSU), the evaluation mapped over time Social Prescribing patients' 
use of hospital resources, including unplanned care, focussing on two cohorts of 
patients in particular: 
 those for whom 12 months of post-referral data was available: 108 patients 
referred between September and December 2012 
 those for whom six months of post-referral data was available: 451 patients 
referred between September 2012 and June 2013. 
The number of in-patient admissions, Accident and Emergency attendances and 
outpatient appointments before and after referral was counted for both cohorts and 
change compared. 
The analysis identified a clear overall trend that points to reductions in patients' 
use of hospital resources after they had been referred to Social Prescribing: 
 Inpatient admissions reduced by 21 per cent within the 12 month cohort and 
by 14 per cent within the six month cohort. For patients who had been referred 
on to a funded VCS service the reductions were greater: 25 per cent within the 
12 month cohort and 22 per cent within the six month cohort 
 Accident and Emergency attendances reduced by 20 per cent within the 12 
month cohort and by 12 per cent within the six month cohort. For patients who 
had been referred on to a funded VCS service the reductions were greater: 24 
per cent within the 12 month cohort and 16 per cent within the six month cohort. 
 Outpatient appointments reduced by 21 per cent within the 12 month cohort 
and by 15 per cent within the six month cohort. For patients who had been 
referred on to a funded VCS service the reductions were greater within the 12 
month cohort (29 per cent) but less within the six month cohort (four per cent). 
An overview of the analysis is provided in Table 1. 
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Table 1: Overview of change in per patient utilisation of hospital resources 
 
All patients referred to Social Prescribing Patients referred to a grant funded VCS provider 
Before 
referral 
After referral Change % change 
Before 
referral 
After referral Change % change 
12 month cohort:*         
No of in-patient admissions 1.46 1.17 -0.30 21 1.45 1.10 -0.36 25 
No of A&E attendances 1.94 1.56 -0.39 20 2.19 1.67 -0.52 24 
No of outpatient appointments 1.70 1.30 -0.36 21 1.90 1.36 -0.55 29 
6 month cohort:**         
No of in-patient admissions 0.59 0.51 -0.08 14 0.58 0.44 -0.13 22 
No of A&E attendances 0.76 0.67 -0.09 12 0.75 0.63 -0.12 16 
No of outpatient appointments 0.74 0.63 -0.11 15 0.72 0.69 -0.03 4 
 
* 108 patients 
** 451 patients 
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Although these findings should be viewed positively, particularly in light of the 
consistent patterns identified, they should also be treated with some caution: there 
are currently too few patients in the sample analysed (in the case of the 12 month 
sample) and too little time has elapsed (in the case of the six month sample), to 
produce findings that are statistically significant. In addition, there is not currently a 
control group against which to compare Social Prescribing patients. Plans for future 
analysis include: 
 analysis of additional patient cohorts: for example, patients who were referred 
towards the end of the Pilot, and patients referred to different types of services 
 analysis of a longer time series: of up to two years pre- and post-referral to 
Social Prescribing 
 development of a robust control group, through administrative data sources and 
statistical matching procedures 
 access to data on use of social care and residential care by Social Prescribing 
patients and carers, in order to assess a wider series of impacts. 
2.2. Social impact 
The social impact (i.e. outcomes for patients) of the Social Prescribing Pilot was 
explored through analysis data collected by VCSAs using a well-being outcome tool, 
and case studies with five service providers, including qualitative interviews with 
beneficiaries and their carers (17 interviews in total). 
Well-being 
The well-being outcome tool measured patients' well-being and their progress 
towards self-management of their condition through eight measures using a five 
point scale. Analysis focussed on 280 patients whose well-being measures had been 
followed-up after 3-4 months: 83 per cent of these patients had experienced 
positive change in at least one outcome area. When the results were broken down 
by category it showed that progress was made against each outcome measure and a 
majority of low-scoring patients (with a baseline score of two or less) made progress: 
 feeling positive: 35 per cent made progress; of the patients with a low baseline 
score 61 per cent made progress 
 lifestyle: 25 per cent made progress; of the patients with a low baseline score 
65 per cent made progress 
 looking after yourself: 24 per cent made progress; of the patients with a low 
baseline score 60 per cent made progress 
 managing symptoms: 21 per cent made progress; of the patients with a low 
baseline score 57 per cent made progress 
 work, volunteering and other activities: 49 per cent made progress; of the 
patients with a low baseline score 54 per cent made progress 
 money: 21 per cent made progress; of the patients with a low baseline score 76 
per cent made progress 
 where you live: 20 per cent made progress; of the patients with a low baseline 
score 78 per cent made progress 
 family and friends: 27 per cent made progress; of the patients with a low 
baseline score 69 per cent made progress. 
An overview of the analysis is provided in Table 2. 
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Table 2: Overview of well-being outcome measure baseline and distance travelled data 
Outcome area 
Baseline Distance travelled 
Count Mean 
Low scores*  
(%) 
Count Mean 
Progress made  
All 
(%) 
Low scores  
(%) 
Feeling positive 819 3.08 30 280 3.62 35 61 
Lifestyle 819 3.39 19 280 3.78 25 65 
Looking after yourself 819 3.58 14 280 3.93 24 60 
Managing symptoms 819 3.43 18 280 3.65 21 57 
Work, volunteering and social groups 819 2.49 45 280 3.15 49 54 
Money 819 4.05 10 280 4.39 21 76 
Where you live 819 4.07 8 280 4.39 20 78 
Family and friends 819 3.71 13 280 3.83 27 69 
*A low score is defined as a baseline score of two or less 
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The distance travelled by Social Prescribing patients across a range of outcomes 
after three-four months demonstrates the potential of social interventions to address 
some of the key psycho-social determinants of health. Importantly, the greatest 
progress was made against the lowest scoring outcome areas (work, volunteering 
etc., and feeling positive); and a majority of low scoring patients made progress. This 
reflects positively on both the effectiveness of the Social Prescribing assessment and 
referral process and the ability of commissioned services to meet the specific social 
needs of patients. 
Case studies 
The case study interviews provided specific examples of the social impact and 
outcomes of Social Prescribing services for beneficiaries and their carers. These 
outcomes can be grouped in four broad themes of increased well-being, reduced 
social isolation and loneliness, increased independence, and access to wider welfare 
benefits: 
 Improved well-being: the case studies revealed numerous examples of 
improvements in patients' and carers' general sense of well-being, but also 
specifically in the area of mental well-being, particularly associated with anxiety 
and depression and personal confidence and self-efficacy. 
"If it wasn’t for the group, I might not be here now because I’d been that down 
and depressed….just getting out of the house has helped me with the fear, 
anxiety…talking to people lifts your mood and forget about problems at home." 
 Reduced social isolation and loneliness: case study interviews highlighted 
the importance of linking people with limited mobility and social contact with the 
wider community, either through accessing community activities (for the more 
mobile) or through befriending and other services provided in patients' homes. 
"It’s someone coming to talk to me and with me and they acknowledge 
me…because you can sit and stare at space and people take no notice 
whatsoever…I feel like I belong to a society." 
 Increased independence: a number of interviewees whose mobility was limited 
were able to become more independent as a result of improvements in their 
physical health. There have also been examples of beneficiaries becoming 
involved in independent social and community action since accessing services. 
"I was on my own, I was totally on my own…Each day I’m getting better and 
better…before I could hardly walk…I’m feeling very positive, each day I get up 
and I just can’t believe how much I’ve come on." 
 Access to wider welfare benefits: a number of case study participants 
highlighted the importance of advocacy services in improving their (and their 
carers) awareness of various benefits that could be available to them and 
supporting them to make applications for benefits such as Direct Payments. This 
was seen as an important step in the realisation of other outcomes, such as 
improved well-being and independence. 
2.3. Economic and social cost-benefits 
The evaluation also involved an analysis of the economic and social benefits of the 
Social Prescribing Pilot: economic benefits were estimated based on the reductions 
in use of hospital care; social benefits were estimated based on the well-being 
outcome data and a survey of Social Prescribing funding recipients. 
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Economic Benefits 
A number of positive benefits (cost reductions) to commissioners linked to the Social 
Prescribing Pilot have been estimated on the basis that the benefits identified lasted 
at least one year: 
 estimated total cost reductions by the end of the Pilot: 
- £552,000 
- a return on investment of 50 pence for each pound (£1) invested 
 total cost reductions for patients referred to funded VCS services by the 
end of the Pilot: 
- £423,000 
- a return on investment of 38 pence for each pound (£1) invested 
 potential cost reductions of £415,000 in the first year post-referral when the 
service is running at full capacity2 
 based on these cost reductions, if the benefits identified are fully sustained over 
a longer period, the costs of delivering the service for a year would be 
recouped after 18 to 24 months  
 the longer-term cost reductions for commissioners for each full year of 
service delivery could be much higher: 
- if the full benefits last for five years they could lead to total cost reductions 
of £1.9 million: a return on investment of £3.38 for each pound (£1) 
invested 
- if the benefits are sustained but drop-off at a rate of 20 per cent each year 
they could lead to total cost reductions of £1.2 million: a return on 
investment of £2.08 for each pound (£1) invested 
- if the benefits are sustained but drop-off at a rate of 33 per cent each year 
they could lead to total cost reductions of £807,000: a return on investment 
of £1.41 for each pound (£1) invested. 
It is important to emphasise that at this stage these figures are estimates based on 
partial data on a sub-set of Social Prescribing beneficiaries. It will be possible to 
refine these estimates in future years once a longer time period has elapsed. 
Social Benefits 
A number of social benefits associated with Social Prescribing were estimated: 
 the well-being benefits for Social Prescribing patients 
 the volunteering undertaken in the delivery of funded Social Prescribing services 
 the additional welfare benefits claimed by patients referred to funded Social 
Prescribing services 
 additional funding accessed by funded VCS services providers that could be 
attributed to their involvement in the Pilot. 
Financial proxies were used to provide a monetised assessment of these benefits 
based on the methodological techniques associated with social return on investment 
(SROI) analysis.3 The findings show the following: 
                                               
2
 This is based on the estimated savings for the second year of the Pilot i.e. the first full year of delivery 
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 the estimated value of well-being benefits: 
- between £819,000 and £920,000 by the end of the pilot 
- potential well-being value of between £660,000 and £742,000 in the first 
year post-referral when the service is running at full capacity4 
- the potential for positive social return on investment during the first year 
following referral to Social Prescribing 
 the estimated value of volunteering: 
- £81,000 based on the national minimum wage 
- £148,000 based on the national median wage 
- an additional £0.16 - £0.26 (16 - 26 pence) for each pound (£1) invested in 
the pilot by the CCG 
 the estimated value of additional welfare benefits claimed: 
- funded VCS services support Prescribing Patients to claim an additional 
£350,000 in welfare benefits over the course of the pilot 
- benefits claimed included Attendance Allowance, Direct Payments, Carer's 
Allowance, Housing Benefit, Personal Independence Payment, 
Employment Support Allowance 
 the estimated value of additional funding accessed by funded VCS service 
providers: 
- three funded VCS service providers were able to secure additional funding 
as a result of their Social Prescribing grant: one provider received £180,000 
from the Big Lottery Fund (BLF), one received £10,000 from NHS England 
and another received £10,000 from Awards for All  (BLF small grants 
programme). 
- 11 funded VCS service providers reported that Social Prescribing Patients 
had accessed additional services though self-funding or by using their 
Direct Payments or Personal Budgets: the value of this additional income 
was at least £10,000 over the course of the pilot. 
                                                                                                                                                  
3
 Details of the valuation techniques applied are provided in the Full Evaluation Report 
4










This report has provided a detailed assessment of the economic and social impact of 
the Rotherham Social Prescribing Pilot. It builds on an earlier Interim Evaluation 
report which identified emerging lessons from the pilot and provided insights from the 
perspective of key stakeholders. This concluding chapter draws together findings 
from both reports to provide an overall assessment of the Pilot and highlight some 
implications for future service delivery and commissioning. 
3.1. Outcomes for Social Prescribing patients and their carers 
The Pilot reached more than 1,500 local people with long-term health conditions. A 
large majority of these patients and their carers experienced positive health and well-
being outcomes. Social Prescribing patients' and carers' mental health has improved, 
they have become more independent, less isolated, more physically active, and have 
begun engaging with and participating in their local community. They have also been 
able to access a range of welfare benefits that they were previously unaware of. 
Crucially, Social Prescribing services have provided these patients and carers with 
an important first step to engaging with community-based services and wider 
statutory provision that would not otherwise have been aware of or able to access. 
3.2. Outcomes for the public sector 
Patients accessing the Pilot were already frequent users of hospital care and 
assessed as at high risk of requiring unplanned hospital care in the future. As such, 
the effectiveness of Social Prescribing at reducing patients' use of hospital care was 
an important measure of success for local NHS commissioners. So far the evaluation 
evidence is very positive. Social Prescribing patients' use of hospital resources 
reduced by up to a fifth in the 12 months following their referral to Social Prescribing. 
This translates into potential positive financial returns to commissioners within two 
years following the initial referral. At this stage these findings carry an important 
caveat: there are too few patients in the sample analysed and too little time has 
elapsed to produce findings that are statistically significant.  
In addition to these direct health related benefits, the public sector has experienced 
broader outcomes as a result of the Social Prescribing Pilot. For example, patients 
accessing the service were generally more satisfied with the support they received 
and felt better supported to manage their condition. There is also emerging evidence 
that non-health services, in particular social and residential care, benefit from similar 
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3.3. Outcomes for the local voluntary and community sector 
The local voluntary and community sector (VCS) has also benefitted from the Pilot. 
The £0.6 million that was invested in VCS Social Prescribing services was a catalyst 
for innovation in community-level service provision, enabling small organisations 
without a track record in health service provision to access NHS funding for this first 
time. Some of these providers have been able to 'match' their Social Prescribing with 
income from other sources to enhance their provision and improve the overall 
sustainability of their organisation.  
Overall, the Pilot has demonstrated the potential for relatively small community 
based provision to make a positive contribution to local strategic health and well-
being priorities, and ought to provide a strong foundation for these types of providers 
to continue making a positive contribution through commissioned services in the 
future. 
3.4. Implications for future service delivery and commissioning 
The Social Prescribing Pilot, and the evidence collected as part of the evaluation, 
have some important implications and lessons for future public service delivery and 
commissioning involving the VCS in health, social care, and more broadly. 
Demonstrating social value through commissioning 
Under the provisions of the Public Service (Social Value) Act 2012 statutory bodies 
are required to consider social value at all stages of the commissioning and 
procurement process. This evaluation has demonstrated the types of social value 
that can be created through public services commissioned through the VCS. These 
include reductions in the utilisation and cost of public services, improvements in the 
health and well-being of local people, independent community engagement and 
social action, wider economic benefits in the form of welfare entitlements and funding, 
and a more sustainable, vibrant and innovative local VCS. It shows that social value 
is accrued by a range of different stakeholders and not just commissioners and 
beneficiaries. Local statutory bodies should therefore be encouraged to consider the 
social value that could accrue to a range of different stakeholders in the service 
being commissioned, and ensure that this is embedded in procurement processes. 
The role of local infrastructure in micro-commissioned community services 
The central role played in the Social Prescribing Pilot by VAR has come through very 
clearly throughout the evaluation. Commissioners, health and care professionals and 
VCS providers have been overwhelmingly positive about VAR's role in delivering the 
Pilot. In particular they have valued VAR's professionalism, independence, 
adaptability and, perhaps most importantly, their knowledge and understanding of 
the VCS in the borough and how its potential could be unlocked to deliver the Pilot 
effectively. As a result, the Pilot provides a model for future 'micro-commissioning' of 
community-level services across a wide range of public service areas. 
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